Share

Webinar: How can current EU policy initiatives pave the way towards treatment optimisation as part of health systems?

The EORTC and the BioMed Alliance, together with MEP Maria da Graça Carvalho and MEP Dolors Montserrat, will organise an interactive webinar on 3 February 2021 from 15:00-17:00 CET on the issue of treatment optimisation.

The online event will bring together important health stakeholders and policy makers with the purpose to analyse how the current policy initiatives can facilitate treatment optimisation studies in the health systems across Europe. The 2-hour webinar aims to explore how treatment optimisation can be facilitated to ensure the most effective, efficient, safe and proportionate treatment adapted to patients’ needs.

Recent health threats such as COVID-19 demonstrated the urgent need for a healthcare system that places the patient at the centre and has the ultimate goal to solve clinical issues. This is distinct from the currently dominant drug-driven approach in treatment development in oncology and in other medical specialities, which tends to neglect important aspects of the use of novel therapies in real-world settings. Clinical research questions such as optimal dose, duration, sequence, combination, and quality of life do not get the attention they deserve. With a patient-centric approach, by contrast, new drugs reaching the market is not an end, but just a start, with studies of treatment optimisation then improving the utilisation of treatments in real-world conditions.

The discussion is timely considering the current health challenges and the preparation of the ambitious European Health Union programme and its policy and legislative measures such as the Pharmaceutical Strategy, the upcoming Horizon Europe, the EU4Health programme, and Europe’s Beating Cancer Plan.

You can register to the event here.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023